BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng H, Du X, Wang L, Chen M. Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol 2020;10:288. [PMID: 32266131 DOI: 10.3389/fonc.2020.00288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Becerra-chauca N, Nieto-gutierrez W, Taype-rondan A. 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting. The Lancet Oncology 2022;23:e100. [DOI: 10.1016/s1470-2045(22)00060-2] [Reference Citation Analysis]
2 Popli P, Gutterman EM, Omene C, Ganesan S, Mills D, Marlink R. Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis. JCO Glob Oncol 2021;7:289-301. [PMID: 33591798 DOI: 10.1200/GO.20.00398] [Reference Citation Analysis]